Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 25-hydroxycholesterol

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with 25-hydroxycholesterol in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Studies
(25-hydroxycholesterol)
Trials
(25-hydroxycholesterol)
Recent Studies (post-2010) (25-hydroxycholesterol)
9,1561875528533243

Protein Interaction Comparison

ProteinTaxonomy1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)25-hydroxycholesterol (IC50)
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)0.3
Sterol regulatory element-binding protein 2Homo sapiens (human)0.3

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ares, M; Cercek, B; Dahlgren, B; HultgÄrdh Nilsson, A; Nilsson, J; Shah, PK; Westman, J1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 25-hydroxycholesterol

ArticleYear
Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor.
    Arteriosclerosis, thrombosis, and vascular biology, 1998, Volume: 18, Issue:1

    Topics: Apolipoprotein A-I; Apoptosis; Carbon Radioisotopes; Cell Count; Cell Survival; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Humans; Hydroxycholesterols; Lysophosphatidylcholines; Muscle, Smooth, Vascular; Phospholipids; Platelet Activating Factor

1998